GlassScriptPhysician profile
Eme Oko Igbokwe
NPI 1346432507
$28,309.21
in general payments reported to CMS, 2019-2025
73 companies · $3,548 in 2025
The $3,548 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,362 · 2020: $3,726 · 2021: $4,634 · 2022: $4,791 · 2023: $4,763 · 2024: $4,486 · 2025: $3,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,321.96 |
| Education | $474.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,851.85 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $2,115.36 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Abbvie INC. | $1,955.19 | 2019-2025 | |
| Amgen INC. | $1,433.88 | 2019-2023 | Aimovig |
| Neurocrine Biosciences, INC. | $1,161.89 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $1,104.61 | 2020-2025 | Gocovri, Gocovri |
| Novartis Pharmaceuticals Corporation | $1,102.52 | 2019-2025 | |
| Pfizer INC. | $1,088.74 | 2019-2025 | |
| Emd Serono, INC. | $996.03 | 2019-2025 | Mavenclad, Mavenclad |
| Lilly USA, LLC | $900.84 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Lundbeck LLC | $779.11 | 2019-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $761.22 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $679.88 | 2019-2024 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $663.89 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Csl Behring | $649.50 | 2019-2025 | Hizentra |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eme Igbokwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.